Combining an FGF21 Drug With Semaglutide Produces Super-Additive Weight Loss and Liver Healing in MASH Mice
Low-dose zalfermin plus low-dose semaglutide produced 18% weight loss in MASH mice — triple what either drug achieved alone — while also improving liver inflammation and fibrosis markers.
Quick Facts
What This Study Found
Combining low-dose zalfermin (an FGF21 analog) with low-dose semaglutide produced super-additive weight loss of 18% in MASH mice — far exceeding either drug alone at the same doses (zalfermin -6%, semaglutide -4%). The combination was equally effective as high doses of either drug given alone.
Beyond weight, the low-dose combination improved liver enzymes, cholesterol, triglycerides, liver inflammation score (NAS), steatosis, and fibrosis gene expression markers more than either low-dose monotherapy and more than high-dose semaglutide alone. This supports combining FGF21 analogs with GLP-1 drugs for MASH treatment.
Key Numbers
n=11-12 per group · Combination weight loss: -18% · Zalfermin alone (low): -6% · Semaglutide alone (low): -4% · High-dose zalfermin: -16% · High-dose semaglutide: -15% · 8-week treatment · Biopsy-confirmed MASH model
How They Did This
Used Amylin liver NASH diet-induced obese mice with biopsy-confirmed MASH and fibrosis. Groups received daily subcutaneous vehicle, low or high-dose zalfermin, low or high-dose semaglutide, or low-dose combination for 8 weeks. Pre- and post-treatment liver biopsies allowed within-subject comparison. Endpoints: body weight, plasma/liver biochemistry, NAS scoring, fibrosis staging, quantitative histology, and liver RNA sequencing.
Why This Research Matters
MASH (formerly NASH) is the most common liver disease globally and a leading cause of liver transplants, yet treatment options are limited. GLP-1 drugs like semaglutide help with weight loss but have modest direct liver effects. FGF21 analogs like zalfermin directly target liver metabolism but don't produce much weight loss. Combining them addresses both problems at lower doses, potentially reducing side effects while maximizing liver benefit — a strategy now entering clinical trials.
The Bigger Picture
The MASH drug landscape is rapidly evolving, with resmetirom (a thyroid receptor agonist) becoming the first approved treatment. FGF21 analogs and GLP-1 drugs are both in late-stage trials. This study suggests combination therapy may be the future — using lower doses of complementary drugs to maximize liver benefits while minimizing individual drug side effects. Several pharma companies are pursuing similar combination strategies.
What This Study Doesn't Tell Us
Mouse model study — MASH drug responses in mice don't always translate to humans. The AMLN diet model creates MASH through extreme diet manipulation, which differs from human disease development. Only 8-week treatment duration; chronic liver disease may require longer treatment. Specific dose ratios that are optimal in mice may not translate directly to human dosing. Only one combination dose ratio was tested.
Questions This Raises
- ?Will the super-additive effect seen in mice translate to human patients in clinical trials?
- ?Could this combination reduce the need for high-dose semaglutide, potentially lowering GI side effects?
- ?How does zalfermin plus semaglutide compare to resmetirom (the first FDA-approved MASH drug) for liver fibrosis?
Trust & Context
- Key Stat:
- -18% weight loss (super-additive) Low-dose combination achieved triple the weight loss of either drug alone, matching high-dose monotherapy results
- Evidence Grade:
- This is a preclinical animal study using a validated MASH mouse model with biopsy-confirmed disease. While the study design is rigorous (within-subject biopsy comparison, multiple dose levels), translation to human clinical outcomes requires Phase II/III trials.
- Study Age:
- Published in 2025, this represents current preclinical development supporting combination therapy approaches for MASH. Clinical trials of FGF21-GLP-1 combinations are expected or underway.
- Original Title:
- The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.
- Published In:
- PloS one, 20(10), e0331665 (2025)
- Authors:
- Norlin, Jenny, Dermit, Maria, Sidiropoulos, Nikos, Galsgaard, Elisabeth D, Hansen, Henrik H, Feigh, Michael, Veidal, Sanne S, Latta, Markus, Henriksson, Emma, Andersen, Birgitte
- Database ID:
- RPEP-12819
Evidence Hierarchy
Frequently Asked Questions
What is MASH and why is it hard to treat?
MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) is a severe form of fatty liver disease where fat buildup causes inflammation and scarring. It can progress to cirrhosis and liver cancer. Until 2024, there were no FDA-approved treatments. The disease involves multiple pathways — fat accumulation, inflammation, and fibrosis — which is why combination drugs targeting different pathways may work better than single drugs.
What does 'super-additive' mean in drug combinations?
If Drug A produces 6% weight loss and Drug B produces 4%, you'd expect combining them to produce roughly 10% (additive). Super-additive means the combination produced 18% — significantly more than the sum of individual effects. This suggests the two drugs activate complementary biological pathways that amplify each other's benefits.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12819APA
Norlin, Jenny; Dermit, Maria; Sidiropoulos, Nikos; Galsgaard, Elisabeth D; Hansen, Henrik H; Feigh, Michael; Veidal, Sanne S; Latta, Markus; Henriksson, Emma; Andersen, Birgitte. (2025). The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.. PloS one, 20(10), e0331665. https://doi.org/10.1371/journal.pone.0331665
MLA
Norlin, Jenny, et al. "The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.." PloS one, 2025. https://doi.org/10.1371/journal.pone.0331665
RethinkPeptides
RethinkPeptides Research Database. "The combination of zalfermin and semaglutide has additive th..." RPEP-12819. Retrieved from https://rethinkpeptides.com/research/norlin-2025-the-combination-of-zalfermin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.